LINC00857

Annotated Information

Name

Approved symbol: LINC00857

Approved name: long intergenic non-protein coding RNA 857

HGNC ID: HGNC:45114

RefSeq ID: NR_038464

Ensembl ID: ENSG00000237523

LncBook ID: HSALNT0165271

Chromosome

10q22.3

Characteristics

LINC00857 expression in MIBC

Please input characteristics information here.

Expression

Was found to be upregulated in tumors from bladder cancer patients that did not respond to platinum‐based chemotherapy^[1].

Was identified as one of the most upregulated lncRNAs in lung cancer^[1].

High LINC00857 expression was associated with shorter overall survival of patients with lung cancer^[1].

Regulation

Please input regulation information here.

Function

Effect of LINC00857 on cisplatin sensitivity

LINC00857 plays an important role in the regulation of response to platinum‐based chemotherapy. LINC00857 potentially could serve as a novel prognostic and predictive biomarker and might be a therapeutic target to overcome cisplatin resistance in patients with MIBC^[1].

It is likely that LINC00857 regulates the expression of LMAN1 and PPP2R5E and other target genes by affecting mRNA stability or promoting its translation leading to resistance to platinum‐induced apoptosis^[1].

Disease

bladder cancer^[1]
lung cancer

Evolution

Please input evolution information here.

Labs working on this lncRNA

Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.
Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands.

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 Dudek AM, van Kampen JGM, Witjes JA, et al. LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer[J]. Cancer Med, 2018.

Sequence

>gi|336285291|ref|NR_038464.1| Homo sapiens long intergenic non-protein coding RNA 857 (LINC00857), long non-coding RNA

000001  GACCGCGAAG GCCAGCTTCT TCGAAAGGCC CATTTTTCTC CGTGGCTGAG CGAATGCTCC TAGAATACCA CGTTTATAAT  000080
000081  AAATCATGTA GGGTGGAATT CCTGCTGGAT GTATACACCT TTCTGCATCA GAGCTCTTCA AACCCAGAAT GGTGAATAGC  000160
000161  TACCCCTGGG CTTACCCTTT TATAATTTTC AACAAACCTG CGTTTAGCCC CGGCTAGGTG CCAGCAAGTT GCTAGGGACT  000240
000241  GAGGAGGCTC TGCAGAGGAC CCGAGCTGAG GCCCTAATCC TCAAGGCCAA TGGCAGGGGT CACCGCCCAG GCACCCCCAG  000320
000321  AGAACGCGGT GTGAAGGAAA AGACACCAAA CTCGGTGTTC AAATGTGTGG GATCTATTCT AGTTCTGATT CTGACACTTG  000400
000401  CAAGTCATGC ATCCTCCGAG CCTCGGCTTT CTCACCTATA AAATCTTCAA CGTGACCTAT AAAAATCCAT AAAATCACCC  000480
000481  CTGCTTCATT GTTTCCCAGG GCTCATAGAA ACATCATACA AGGTGGAGAA GAGTACCCAA GAAGGACAAG CTTGGAATGG  000560
000561  GGCCCCCTCC CCAGGCTGGA GATCAGACAT TGTTGGAGAA GGTATCATTG CAGCCCCCTA CATAGCAGAG AGATTTGCTG  000640
000641  AGTTGCATAG TCTAGAGCTG GTTGCAATTA TTGGACAAGC AGGAAACAAA CCTCCACAGC CCATGCGAGC CACACTGCTG  000720
000721  GGTTGAGTGT ATGAGCATGT AGAATGATTG GGTCTCCAGT GCGGACAGAA GGCATGGATC GCGTGGTGCC TGTGTTGGGA  000800
000801  GGATACTAAG AGGGCGATCA CCATGCCAGG ACAAGACTAG TTGCCTGGGA TCTTCTGGGC ACGTGACTGG AGCAGAGTAC  000880
000881  CACTGGATCT CCTCACACCA GCCAGACCCA GGAAGAGAAG CTCCTTTCAC CTGCACTGTT CTCTCAGCAC CCTCCACGGA  000960
000961  GAAAGCTTCA TGTTATGCTT AGTGTACAGG AGAAATGCTC ATGGGAATCC TGTCCATTAT CACAGAGCAG GTATTAGTGG  001040
001041  GTGAATATGG AGCTGAGAAG TAATAAGTTG TAACTGGCAT AGATATCATG GGGATATTTG AAGAACGCTG TGAACACATA  001120
001121  TGCATGGGTC CATGTATTCA TGAGTGTGCA CATATGTGTA ATTATTCATA CAATTCATGG TGGATACTAC TTCGAGGGTG  001200
001201  TTCACAGACC CCAGGCAGAG AGCGCCTGGA GGGAAAATTA TCCAAGGCAG GCCCATTCAT AGTTCCAGGA CAGCCAGAAG  001280
001281  AAAGCCTCCG TTAAGCACCA GAAGTCTCCG GGGCAGGTGG GGCCAGGCAG CATGAAAGAA TTGGCCGCAA GAGTTCCAAA  001360
001361  CCCTGTCCCA ATTATGGAGG GTGACTTTTC TTTGTCCTCC TTCTCCATTC CCTTCCATAT TGCTCATGCA TCCAAAGGGA  001440
001441  GACCTGAAGA CTCTCTAGCA GGGCAAGGCC ATTTTCTTTT GGCATTTTTC TCTCCCCAGA GTCTAGCTGA TTATCAGCTT  001520
001521  AGACACACAG CAGGCTATGT GCTGTGAACA ACAGGCATCC TGGGTTATTT TACAAACTCA TGGATAGTCA TTTTGAAACC  001600
001601  ACCTTTGCAA AATTGTGACT GAAACAGTGA AAGAGAGCTA ACTTAACCAG CTCCATCTTG TTTCTAACCT CCAAGCTGTC  001680
001681  TTTGTTCATT CCTGGGCGTA GGCTGAACTA ACTTTGGGAG AAACTTAGTT TGTAGTTATA GTTTAAACAA AGACTGTGAC  001760
001761  AGCCCTTTCC CAATGCAGAC CTCCTTCTTG TCTGGGGACT AGACTAACAT TAGCCACAGG ATTAGAAATT ACGGTTTAGG  001840
001841  AGTCACGCAG CTGGAGGCTA CAAGATTCTG ACCCTCCCTA AACTGCTTCT AAGATCAGTG CTTGAGACAT GTTGCAGACC  001920
001921  CCGCACTTGC TGGATCAGCT GACGCCACAC AGATGGATAA ACTGCCTCGT CTGATCTTGT GGCCCCCACC CGGGAACTGA  002000
002001  CGAAGCGCAA GAAGACAGCT TCGACTCCCT GTGAGTTCAT CCCTGACCAA CCAGCACTCC TGGCTCACTG GCTTCCCCCT  002080
002081  ACCAAGTTAT GCTTAAAAAT TCTGCTCCCC GAATTCTCGA GGAGACTGAT TTGAGTGATA ATAAAACTCC AGTCTCCCG

[ref1-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 Dudek AM, van Kampen JGM, Witjes JA, et al. LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer[J]. Cancer Med, 2018.

[1]